Ravindran Kanesvaran, Chairman of the Division of Medical Oncology at the National Cancer Centre Singapore, and Distinguished Professor of Geriatric Oncology at Duke-NUS Medical School, shared a post on LinkedIn:
“Yesterday I had the privilege of leading the ESMO Pan-Asian Guidelines Adaptation (PAGA) meeting on renal cell carcinoma in Singapore, bringing together experts from 10 Asian oncology societies and ESMO to refine RCC guidance for our region.
Over a full day, we stress-tested the ESMO RCC guidelines against real-world Asian practice: differing access to IO/TKI combinations, variability in diagnostics and biomarkers, and health-system constraints from China to Southeast Asia. Our goal was simple but ambitious – to deliver clear, consensus-based recommendations that are scientifically robust and implementable in diverse Asian health systems, ultimately improving outcomes for patients with advanced kidney cancer.
The adapted RCC recommendations and regional access analysis will now move rapidly into manuscript development with an anticipated publication in 2026. Grateful to all colleagues and societies who contributed their time, data and perspective to this important effort.”
More posts featuring Ravindran Kanesvaran.